Clinical Trials Directory

Trials / Completed

CompletedNCT01080040

To Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Multiple Sclerosis Patients

Observational Study to Assess the Prevalence of Spasticity and the Impact on the Quality of Life in Patients With Multiple Sclerosis in Argentina

Status
Completed
Phase
Study type
Observational
Enrollment
150 (actual)
Sponsor
Merck KGaA, Darmstadt, Germany · Industry
Sex
All
Age
21 Years – 60 Years
Healthy volunteers
Not accepted

Summary

This study is observational, non-controlled, multicentric and prospective, without experimental intervention or control. As part of the usual management of the subjects, scales will be used for the assessment of the spasticity and the quality of life (QoL). The purpose of this observational study is to assess the incidence of spasticity in a group of subjects with Relapsing Remitting Multiple Sclerosis (RRMS) in Argentina and the way it affects the QoL of these subjects.

Detailed description

One of most frequently observed symptoms in subjects with MS is spasticity. Spasticity is defined as an abnormal velocity-dependent increase in muscle tonic stretch reflexes due to an amplified reactivity of motor segments to sensory input. It is part of one of the components of the superior motoneurone syndrome and it may cause muscle rigidity and disability. The spasticity, which could be measured in electrophysiological, biomechanical and clinical terms, has a significant prevalence. It is a frequent cause for consultation among subjects with MS and, consequently, has a significant impact on the QoL. Men and those subjects with MS of longer duration are the most affected by spasticity. The aim of this study is to assess the impact that spasticity has on the QoL of subjects with MS. The total duration of the study is 24 months. The recruiting period will be 12 months. Once the recruiting time is over, the collection of data will continue during the full 24 months period that was planned.

Conditions

Timeline

Start date
2008-08-01
Primary completion
2013-03-01
Completion
2013-03-01
First posted
2010-03-03
Last updated
2013-10-16

Locations

1 site across 1 country: Argentina

Source: ClinicalTrials.gov record NCT01080040. Inclusion in this directory is not an endorsement.